Research graph
References from ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis. Local targets link to admitted publications; unresolved targets remain external evidence.
Metabolic dysfunction-associated steatotic liver disease
10.1016/j.clinme.2025.100526 · 2025 · External reference
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
10.1038/s41573-024-01084-2 · 2025 · External reference
Unresolved reference
2024 · External reference
MASLD development: from molecular pathogenesis toward therapeutic strategies
10.1097/cm9.0000000000003629 · 2025 · External reference
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
10.1038/s41423-025-01307-5 · 2025 · External reference
Efruxifermin in compensated liver cirrhosis caused by MASH
10.1056/nejmoa2502242 · 2025 · External reference
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
10.1002/hep.29466 · 2018 · External reference
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis
10.1016/j.jhep.2024.03.014 · 2024 · External reference
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
10.1016/j.metabol.2015.12.012 · 2016 · External reference
Pathogenesis of NASH: the impact of multiple pathways
10.1007/s11901-018-0425-7 · 2018 · External reference
The first MASH drug therapy on the horizon: current perspectives of resmetirom
10.1111/liv.15930 · 2024 · External reference
Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis
10.1186/s12962-026-00741-0 · 2026 · External reference
FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid
10.1002/med.21991 · 2024 · External reference
The complexity and multiplicity of the specific cAMP phosphodiesterase family: PDE4, open new adapted therapeutic approaches
10.3390/ijms231810616 · 2022 · External reference
Role of cAMP and phosphodiesterase signaling in liver health and disease
10.1016/j.cellsig.2018.06.005 · 2018 · External reference
The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma
10.1186/1465-9921-5-4 · 2004 · External reference
Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway
10.1002/mnfr.201500016 · 2015 · External reference
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats
10.1111/fcp.12530 · 2020 · External reference
Pentoxifylline and its association with kaempferol improve NASH-associated manifestations in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms
2022 · External reference
Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis
10.3748/wjg.v20.i2.569 · 2014 · External reference
A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
10.2165/00003495-198734010-00003 · 1987 · External reference
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD: a randomized, placebo-controlled phase Ib/IIa trial
10.1038/s41467-023-42162-0 · 2023 · External reference
Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure-response approach
10.1016/j.ejps.2024.106808 · 2024 · External reference
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
10.1002/hep.20701 · 2005 · External reference
Discovery of a peripheral 5HT2A antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitis
10.1038/s41467-024-44874-3 · 2024 · External reference
Unresolved reference
2015 · External reference
The medicinal chemistry of caffeine
10.1021/acs.jmedchem.1c00261 · 2021 · External reference
Structural basis for the activity of drugs that inhibit phosphodiesterases
10.1016/j.str.2004.10.004 · 2004 · External reference
Unresolved reference
External reference
Pharmacokinetics of orally administered pentoxifylline in humans
10.1002/jps.2600750111 · 1986 · External reference
TNF-alpha messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis
10.1684/ecn.2012.0313 · 2012 · External reference
A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
10.1038/s41467-024-50660-y · 2024 · External reference
Reduced serum cholesterol and triglyceride levels in a choline-deficient L-Amino acid-defined high-fat diet (CDAHFD)-Induced mouse model of non-alcoholic steatohepatitis (NASH)
10.1248/bpb.b19-00338 · 2020 · External reference
Mangiferin relieves CCl4-induced liver fibrosis in mice
2023 · External reference
State that Kupffer cells are associated with apoptosis, inflammation, and fibrotic effects in hepatic fibrosis in rats
10.1038/labinvest.2010.123 · 2010 · External reference
Transcriptome and gut microbiota profiling analysis of ANIT-Induced cholestasis and the effects of da-huang-xiao-shi decoction intervention
10.1128/spectrum.03242-22 · 2022 · External reference
Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles
10.3109/08982100903161456 · 2010 · External reference
Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration
10.2460/ajvr.2000.61.631 · 2000 · External reference
Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo, Hepatol
2025 · External reference
Butein alleviates non-alcoholic steatohepatitis in leptin-deficient mice by modulating the PDE4/cAMP/p-CREB pathway
10.2147/dddt.s530855 · 2025 · External reference
Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
10.1016/j.bbrc.2024.150170 · 2024 · External reference
A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases
10.1097/hep.0000000000000999 · 2025 · External reference
A novel phosphodiesterase 5 inhibitor, CPD1, alleviates liver fibrosis by modulating the Akt/NF-κB pathway to inhibit activated hepatic stellate cells
2025 · External reference
Ameliorative effects of sildenafil against carbon tetrachloride induced hepatic fibrosis in rat model through downregulation of osteopontin gene expression
10.1038/s41598-024-67305-1 · 2024 · External reference
The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats, can
10.1139/cjpp-2018-0338 · 2018 · External reference
Design, synthesis, and evaluation of dihydropyrimidine derivatives as selective PDE1 inhibitors for the treatment of liver fibrosis
10.1021/acs.jmedchem.4c00461 · 2024 · External reference
Mitochondrial NCLX couples glucagon- and PDE2A-dependent signals to regulate hepatic lipid metabolism
10.1016/j.molmet.2026.102433 · 2026 · External reference
Pipeline of new drug treatment for non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease
2024 · External reference
The effects of pentoxifylline on lipopolysaccharide (LPS) fever, plasma interleukin 6 (IL-6), and tumor necrosis factor (TNF) in the rat
10.1016/1043-4666(90)90032-o · 1990 · External reference
Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis
10.1007/s10620-006-9723-y · 2007 · External reference
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
10.1016/j.jhep.2023.07.014 · 2023 · External reference
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis
10.1111/j.1572-0241.2004.40064.x · 2004 · External reference
Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation
10.1177/0091270011433435 · 2013 · External reference
The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase
10.1172/jci117899 · 1995 · External reference
Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease
10.1016/j.cld.2004.04.012 · 2004 · External reference
Beyond insulin resistance in NASH: TNF-alpha or adiponectin?
10.1002/hep.20280 · 2004 · External reference
Alterations of hepatic energy metabolism in murine models of obesity, diabetes, and fatty liver diseases
10.1016/j.ebiom.2023.104714 · 2023 · External reference
Early-life antibiotic exposure aggravates the metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma
10.1186/s12885-024-13136-2 · 2024 · External reference
An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis
10.1111/iep.12008 · 2013 · External reference
Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis
10.1152/ajpgi.00110.2024 · 2025 · External reference
Hepatocyte-, but not myeloid cell-Rictor/mTORC2 deficiency moderately attenuates steatotic liver disease induced by intake of a choline-deficient, amino acid-defined high-fat diet
2026 · External reference
Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4
10.1124/jpet.113.204933 · 2013 · External reference
Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models
10.1172/jci182571 · 2026 · External reference
Liver inflammation and fibrosis
10.1172/jci88881 · 2017 · External reference
Exosomal miRNAs as potential biomarkers to monitor phosphodiesterase 5 inhibitor induced anti-fibrotic effects on CCl4-treated rats
10.3390/ijms22010382 · 2020 · External reference
sGC stimulator (BAY 41-8543) combined with PDE9 inhibitor (BAY 73-6691) reduces renal fibrosis in 5/6 nephrectomized rats
10.1111/bcpt.14103 · 2025 · External reference
SRT1720 alleviates ANIT-induced cholestasis in a mouse model
10.3389/fphar.2017.00256 · 2017 · External reference
Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology
10.1016/j.jhep.2024.01.036 · 2024 · External reference
Estrogen receptor 1 signaling in hepatic stellate cells designates resistance to liver fibrosis
10.1038/s41421-025-00783-3 · 2025 · External reference
The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis
10.1016/j.coph.2011.09.003 · 2011 · External reference
